相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。How I treat acute myeloid leukemia in the era of new drugs
Courtney D. DiNardo et al.
BLOOD (2020)
Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience
Daria Gaut et al.
LEUKEMIA RESEARCH (2020)
The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia
Michael Byrne et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
Erika Morsia et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia
Karamjeet S. Sandhu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies
Esther Schuler et al.
ANNALS OF HEMATOLOGY (2019)
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study
Ron Ram et al.
ANNALS OF HEMATOLOGY (2019)
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis
Suresh Agarwal et al.
HEMATOLOGICAL ONCOLOGY (2019)
Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation
Giacomo Andreani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation
Robert Zeiser et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation
Nour M. Moukalled et al.
BONE MARROW TRANSPLANTATION (2019)
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents
Ibrahim Aldoss et al.
BLOOD ADVANCES (2019)
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation
Christoph Schmid et al.
HAEMATOLOGICA (2018)
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation
Christoph Schmid et al.
HAEMATOLOGICA (2018)
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia
C. Craddock et al.
JOURNAL OF INTERNAL MEDICINE (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Thomas Schroeder et al.
ANNALS OF HEMATOLOGY (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial
Janghee Woo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Charles Craddock et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions-A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
Thomas Schroeder et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan H. Jagasia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT
T. Ruutu et al.
BONE MARROW TRANSPLANTATION (2015)
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation
Marcos de Lima et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
T. Schroeder et al.
LEUKEMIA (2013)
Defining the Intensity of Conditioning Regimens: Working Definitions
Andrea Bacigalupo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine
Thorsten Graef et al.
LEUKEMIA RESEARCH (2007)
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
AH Filipovich et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
分享论文
